Remicade

Samsung Bioepis launches a Remicade knockoff at a 35% discount; FDA OK’s a self-administered version of Benlysta
Samsung Bioepis launches a Remicade knockoff at a 35% discount; FDA OK’s a self-administered version of Benlysta
Endpoints
Samsung Bioepis
Remicade
FDA
biosimilars
JNJ
GSK
Benlysta
lupus
Flag link:
How did Johnson & Johnson beat back Remicade's biosim? Call it the art of the deal
How did Johnson & Johnson beat back Remicade's biosim? Call it the art of the deal
Fierce Pharma
JNJ
Remicade
biosimilars
Pfizer
Inflectra
Flag link:
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Yahoo/Reuters
Novartis
rheumatoid arthritis
generics
Sandoz
Amgen
Enbrel
JNJ
Remicade
AbbVie
Humira
Flag link:
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
Motley Fool
prescription data
Sanofi
Lantus
Roche
Herceptin
Avastin
Celgene
Revlimid
JNJ
Merck
Remicade
Biogen
Rituxan
Amgen
Enbrel
Gilead Sciences
Harvoni
AbbVie
Humira
Flag link:
UK watchdog accuses Merck of restricting biosimilar competition
UK watchdog accuses Merck of restricting biosimilar competition
Drug Delivery Business News
Merck
biosimilars
competition
UK
Remicade
Flag link:
J&J fires off legal salvo to block Samsung's Remicade biosim launch
J&J fires off legal salvo to block Samsung's Remicade biosim launch
Fierce Pharma
JNJ
Samsung Bioepis
Remicade
biosimilar
Flag link:
J&J discloses DOJ investigations into marketing, advisory practices
J&J discloses DOJ investigations into marketing, advisory practices
BioPharma Dive
JNJ
DOJ
drug marketing
Remicade
Olysio
Simponi
Stelara
Flag link:
U.S. prosecutors zero in on J&J marketing, targeting top immunology, hep C meds
U.S. prosecutors zero in on J&J marketing, targeting top immunology, hep C meds
Fierce Pharma
JNJ
drug manufacturing
immunology
hepatitis C
Remicade
Simponi
Stelara
Olysio
Flag link:
Second biosimilar of Remicade approved in the US, but J&J not rattled
Second biosimilar of Remicade approved in the US, but J&J not rattled
BioPharma Dive
Remicade
JNJ
biosimilars
Renflexis
Merck
Samsung Bioepis
Flag link:
J&J's Remicade sees 'very little' biosim erosion, but payers are sticking it to Xarelto
J&J's Remicade sees 'very little' biosim erosion, but payers are sticking it to Xarelto
Fierce Pharma
JNJ
Remicade
biosimilars
payers
Xarelto
Inflectra
Flag link:
How Decline in Remicade Is Affecting Merck’s Immunology Revenues
How Decline in Remicade Is Affecting Merck’s Immunology Revenues
Market Realist
Merck
Remicade
Flag link:
The 19 Best-Selling Prescription Drugs of All-Time
The 19 Best-Selling Prescription Drugs of All-Time
Motley Fool
Lipitor
Humira
Seretide
Remicade
Plavix
Enbrel
Rituxan
Herceptin
Avastin
Nexium
Zyprexa
Flag link:
The 3 Most Important Numbers for Johnson & Johnson
The 3 Most Important Numbers for Johnson & Johnson
Motley Fool
JNJ
devices
Remicade
Flag link:
Pfizer and Celltrion Seek Biosimilar Interchangeability for Crohn’s Disease Drug
Pfizer and Celltrion Seek Biosimilar Interchangeability for Crohn’s Disease Drug
Xtalks
Pfizer
Celltrion
biosimilars
Crohn's Disease
Inflectra
Remicade
Flag link:
Johnson & Johnson May Already Have Its Remicade Replacement Well in Hand
Johnson & Johnson May Already Have Its Remicade Replacement Well in Hand
Motley Fool
JNJ
Remicade
Darzalex
Genmab
Multiple Myeloma
Flag link:
Pfizer, Celltrion pushing for interchangeability with Inflectra
Pfizer, Celltrion pushing for interchangeability with Inflectra
BioPharma Dive
Pfizer
Celltrion
Inflectra
JNJ
biosimilars
Remicade
Flag link:
Pfizer's New Biosimilar Is Off and Running
Pfizer's New Biosimilar Is Off and Running
Motley Fool
Pfizer
biosimilars
Remicade
JNJ
Inflectra
rheumatoid arthritis
Flag link:
New competition took a bite out of J&J’s drug sales, but don’t expect the trend to dominate this earnings season
New competition took a bite out of J&J’s drug sales, but don’t expect the trend to dominate this earnings season
Marketwatch
JNJ
earnings
Remicade
biosimilars
Flag link:
J&J optimistic in spite of biosimilar threat
J&J optimistic in spite of biosimilar threat
BioPharma Dive
JNJ
biosimilars
Remicade
Pfizer
rheumatoid arthritis
Flag link:
J&J posts earnings beat, and says pharma future bright, despite threat to Remicade
J&J posts earnings beat, and says pharma future bright, despite threat to Remicade
Yahoo/Reuters
JNJ
earnings
Remicade
Flag link: